Department of Biotechnology, Rashtrasant Tukadoji Maharaj Nagpur University, India
Leukaemia is the type of the cancer that mainly deals with the formation of the haemo-tissues in the regions like lymphatic system and the bone marrow. Several pathways associated to the leukaemia have been found by the scientists over the globe. Interestingly, the most important and one of the critical pathways is the AKT/PI3K pathway that involves a plethora of the cytokines and the growth factors. This PI3K pathway plays a major in the biological processes like angiogenesis, apoptosis, proliferation of the cells and the signal transduction related events. But, have you ever been intrigued by the fact if this prime pathway can be regulated? If regulated, then what are those key control factors and how can we regulate it in case of blood cancer? Neurofibromin is a protein that is mainly encoded by the NF1 gene with 2818 amino acids with a molecular mass of around 250 - 280 kDa that is involved in the GAP related activities and known to negatively regulate the RAS signal transduction pathway and this pathway plays a major role in the PI3K pathway. So, there is an urgent needed to engineer the RAS protein in order the PI3K activity. Reportedly, the mice that were mutated with the PI3K protein did not form cancers. This review emphasizes on the dominant activity of the Neurofibromin protein engineered by the CRISPR technology that can indirectly regulate the PI3K pathway.
Keywords: Leukaemia; Haemo-Tissues; Lymphatic; Bone Marrow; Signal Transduction; Neurofibromin
Akanksha Awadhesh Singh. “CRISPR-Modified Neurofibromin Can Help Suppress the Leukemic PI3K Signalling Pathway”. EC Microbiology 19.6 (2023): 01-05.
© 2023 Akanksha Awadhesh Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by ECronicon is
licensed under a Creative Commons Attribution
4.0 International License
Based on a work at www.ecronicon.net